Patients with moderate to severe COVID-19 disease with following criteria : <br/ >1. Pregnancy or breast feeding <br/ >2. Serum alanine aminotransferase(ALT) or aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN) <br/ >3. Known severe renal impairment (eGFR ï?¼30 ml/min/1.73 m2 or on continuous RRT (hemodialysis, peritoneal dialysis) <br/ >4. Known severe allergic reactions to tocilizumab or other monoclonal antibodies <br/ >5. Known hypersensitivity to remdesivir <br/ >6. Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months <br/ >7. Absolute neutrophil count (ANC) < 1000/uL at screening <br/ >8. Clinical evidence of active tuberculosis or blood culture proven active secondary infections <br/ >9. Participating in other drug clinical trials <br/ >

Patients with moderate to severe COVID-19 disease with following criteria : <br/ >1. Pregnancy or breast feeding <br/ >2. Serum alanine aminotransferase(ALT) or aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN) <br/ >3. Known severe renal impairment (eGFR ï?¼30 ml/min/1.73 m2 or on continuous RRT (hemodialysis, peritoneal dialysis) <br/ >4. Known severe allergic reactions to tocilizumab or other monoclonal antibodies <br/ >5. Known hypersensitivity to remdesivir <br/ >6. Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months <br/ >7. Absolute neutrophil count (ANC) < 1000/uL at screening <br/ >8. Clinical evidence of active tuberculosis or blood culture proven active secondary infections <br/ >9. Participating in other drug clinical trials <br/ >

N/A

N/A

Patients with moderate to severe COVID-19 disease with following criteria : <br/ >1. Pregnancy or breast feeding <br/ >2. Serum alanine aminotransferase(ALT) or aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN) <br/ >3. Known severe renal impairment (eGFR ï?¼30 ml/min/1.73 m2 or on continuous RRT (hemodialysis, peritoneal dialysis) <br/ >4. Known severe allergic reactions to tocilizumab or other monoclonal antibodies <br/ >5. Known hypersensitivity to remdesivir <br/ >6. Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months <br/ >7. Absolute neutrophil count (ANC) < 1000/uL at screening <br/ >8. Clinical evidence of active tuberculosis or blood culture proven active secondary infections <br/ >9. Participating in other drug clinical trials <br/ >

Patients with moderate to severe COVID-19 disease with following criteria : <br/ >1. Pregnancy or breast feeding <br/ >2. Serum alanine aminotransferase(ALT) or aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN) <br/ >3. Known severe renal impairment (eGFR ï?¼30 ml/min/1.73 m2 or on continuous RRT (hemodialysis, peritoneal dialysis) <br/ >4. Known severe allergic reactions to tocilizumab or other monoclonal antibodies <br/ >5. Known hypersensitivity to remdesivir <br/ >6. Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months <br/ >7. Absolute neutrophil count (ANC) < 1000/uL at screening <br/ >8. Clinical evidence of active tuberculosis or blood culture proven active secondary infections <br/ >9. Participating in other drug clinical trials <br/ >